Trust Signals
All claims below are graded by evidence type. Speculative or mechanistic claims are labeled as such. No precise statistics are cited without a real, traceable source. Regulatory information reflects FDA guidance current as of May 2026. This page does not constitute medical advice.
Key Takeaways
- Hexarelin is a more potent GH secretagogue than ipamorelin at equivalent molar doses, but that potency is paired with greater cortisol, ACTH, and prolactin release in human pharmacology studies.
- Ipamorelin's defining characteristic is selectivity: it stimulates GH release with minimal effect on cortisol, ACTH, or prolactin, a property documented in Bowers' original characterization work.
- Hexarelin binds a second receptor, CD36, giving it off-target cardiac and metabolic effects not shared by ipamorelin. Whether that is a benefit or a liability depends on context.
- No head-to-head human RCT compares ipamorelin and hexarelin for body composition, recovery, or any wellness endpoint. Nearly all comparative claims come from animal data or mechanism extrapolation.
- As of 2023, the FDA removed ipamorelin from its bulk drug substances list for 503A and 503B compounders, making legal access in the US more restricted than it was in prior years.
What Is the Core Difference Between Ipamorelin and Hexarelin?
Ipamorelin vs hexarelin comes down to selectivity versus potency. Ipamorelin is a selective GHS-R1a agonist with minimal off-target hormonal activity. Hexarelin is a more potent GHS-R1a agonist that also activates CD36 and stimulates cortisol and prolactin release in humans. For most research protocols, ipamorelin's cleaner hormonal profile is the practical advantage; hexarelin's potency advantage is partly cancelled by its side-effect burden and faster receptor desensitization.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What Is the Core Difference (direct answer above)
- How Do Both Peptides Work? Mechanism with Numbers
- Evidence Ledger: What Does the Research Actually Support?
- Side Effect Profile Compared
- What Most Pages Get Wrong About These Two Peptides
- The Chemistry Behind the Rules of Thumb
- Honest Head-to-Head Table
- Dosing and Operational Label Literacy
- Regulatory and Sourcing Reality
- FAQ
- Sources
How Do Both Peptides Work? Mechanism with Numbers
Both ipamorelin and hexarelin are synthetic growth hormone secretagogues (GHS) that mimic ghrelin at the GHS-R1a receptor, a Gq/G11-coupled GPCR expressed in hypothalamic and pituitary cells. Activation stimulates phospholipase C, raises intracellular calcium, and triggers GH release from somatotrophs.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s. It was the first GH secretagogue characterized as selective: in Raun et al. (1998), ipamorelin stimulated GH release in rats comparable to GHRP-6 but produced significantly lower ACTH and cortisol responses than GHRP-6 at equivalent effective doses. Molecular weight is approximately 711 Da. Plasma half-life after subcutaneous injection in animal models is roughly 2 hours, though human pharmacokinetic data are limited.
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide developed by Deghenghi and colleagues. In Arvat et al. (1997) and related Endocrine Research Group studies, hexarelin produced GH responses in healthy adults at doses around 2 mcg/kg IV that were among the highest observed for any GHS tested at the time. It also produces measurable cortisol and ACTH increases in humans, unlike ipamorelin. Molecular weight is approximately 887 Da.
The CD36 difference: Hexarelin, but not ipamorelin, binds CD36, a class B scavenger receptor expressed in cardiac myocytes, macrophages, and adipose tissue. Bodart et al. and Muccioli et al. characterized this binding. Animal studies show hexarelin has cardioprotective effects in ischemic injury models via CD36-dependent signaling, independent of GH release. This is a genuine mechanistic distinction. What it does NOT prove is that hexarelin produces meaningful cardiac protection in healthy humans at research doses.
Evidence Ledger: What Does the Research Actually Support?
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Both peptides acutely raise serum GH in humans | Human pharmacology studies (small N, mostly single-dose) | Positive | Moderate |
| Hexarelin is a more potent GH stimulus than ipamorelin at equivalent doses | Animal studies; indirect human comparisons | Positive (hexarelin stronger) | Moderate |
| Ipamorelin has lower cortisol/ACTH effect than GHRP-6 and hexarelin | Animal RCT (Raun et al. 1998); supported by mechanistic data | Positive | Moderate |
| Hexarelin raises cortisol and prolactin in humans | Human pharmacology studies (Arvat et al. and others) | Positive | Moderate |
| Hexarelin binds CD36 and is cardioprotective in ischemia models | Animal models; in vitro binding studies | Positive (animal) | Low (human translation unknown) |
| Either peptide improves body composition in healthy adults | Mechanism extrapolation; no human RCT for wellness indications | Speculative | Very Low |
| Hexarelin desensitizes GHS-R1a faster than ipamorelin | Animal and in vitro data; pharmacological inference | Positive (hexarelin worse) | Low |
| Ipamorelin plus CJC-1295 produces synergistic GH release | Pharmacological rationale; anecdotal clinical reports | Positive (plausible) | Low |
Side Effect Profile Compared
Ipamorelin side effects documented in research include transient flushing, injection site irritation, and mild headache. Its defining advantage is the absence of significant cortisol, ACTH, or prolactin stimulation at therapeutic doses. Water retention is possible via downstream IGF-1 effects. The selectivity profile is its primary clinical selling point.
Hexarelin side effects include all of the above plus cortisol and prolactin elevation, which are dose-dependent and documented in human studies. Elevated cortisol with chronic use is a legitimate concern for protocols aimed at recovery or lean mass retention, as cortisol is catabolic to muscle. Prolactin elevation raises the question of gynecomastia risk with prolonged use, though this has not been rigorously studied. Hunger stimulation via ghrelin pathway activation occurs with both peptides but may be more pronounced with hexarelin.
Desensitization: Repeated dosing with high-intrinsic-efficacy GHS-R1a agonists causes receptor internalization and blunted GH response over time. This effect is documented more clearly for GHRP-6 and hexarelin than for ipamorelin in the literature. Cycling (for example, five days on, two days off, or longer periodic breaks) is a common research protocol response to this concern.
What Most Pages Get Wrong About These Two Peptides
Most comparison pages treat hexarelin's potency as a straightforward advantage. It is not. Here is what they omit:
1. Potency and selectivity trade off directly. Hexarelin's greater GHS-R1a efficacy is the same property driving greater receptor desensitization. You cannot separate them. The peptide that gives you the biggest single GH spike is also the one that blunts your pituitary response fastest with repeated use.
2. The cortisol issue is not trivial for body composition goals. Chronically elevated cortisol opposes lean mass accrual. A peptide that raises GH but also raises cortisol delivers a partially self-defeating signal for people using it for body composition. Ipamorelin's selectivity advantage is directly relevant here.
3. The CD36 cardiac story is real but misrepresented. Hexarelin does bind CD36 and animal data are interesting. But no published human RCT confirms clinically meaningful cardiac benefit at research doses. Most pages present the animal finding as if it translates directly. It does not, and honest reporting requires the caveat.
4. Bioavailability by route matters enormously. Both peptides are nearly inactive orally due to peptide bond hydrolysis in the GI tract and first-pass degradation. Subcutaneous injection is the only established research administration route. Intranasal and transdermal routes have very poor bioavailability for peptides of this molecular weight and polarity. Any product claiming oral delivery of these peptides is not delivering the intact peptide in meaningful quantity.
5. Purity variance in the research chemical market is large. Third-party testing of peptide samples from online research chemical suppliers has repeatedly found purity below stated values, incorrect molecular weights on mass spec, and contamination with residual synthesis reagents. A COA from the selling vendor is not independent verification.
The Chemistry Behind the Rules of Thumb
Why store at 2 to 8 degrees Celsius after reconstitution: Both peptides are susceptible to hydrolysis of peptide bonds and asparagine deamidation at elevated temperatures. These reactions follow Arrhenius kinetics: rate roughly doubles for every 10 degree Celsius rise. At room temperature (approximately 22 degrees Celsius), degradation is meaningfully faster than at refrigerator temperature. Lyophilized powder is more stable because it lacks the water needed for hydrolysis. Once reconstituted, you have introduced that water.
Why bacteriostatic water and not sterile water: Bacteriostatic water contains 0.9 percent benzyl alcohol, a preservative that inhibits microbial growth in the reconstituted vial over the multi-week use period. Sterile water lacks this and should be used for single-dose preparations only. The peptide chemistry itself is not affected by benzyl alcohol at these concentrations.
Why avoid vitamin C in the same syringe: Ascorbic acid (vitamin C) is a reducing agent. It can donate electrons to oxidizable residues, particularly tryptophan and methionine side chains. Hexarelin contains tryptophan (Trp) residues in its sequence. Oxidation of tryptophan changes the side chain structure and can reduce or eliminate GHS-R1a binding affinity. This is a real degradation pathway, not just a precautionary myth.
Why avoid light exposure: Both peptides contain aromatic amino acids (D-2-Nal in ipamorelin, D-2-methyl-Trp and D-Phe in hexarelin) that absorb UV light. Photolytic degradation of aromatic residues generates reactive oxygen species that trigger further peptide oxidation. Amber vials and opaque storage containers meaningfully extend shelf life.
Honest Head-to-Head Table
| Property | Ipamorelin | Hexarelin | Winner (or tie) |
|---|---|---|---|
| GH release potency | Moderate | Higher | Hexarelin |
| Cortisol/ACTH elevation | Minimal | Measurable in humans | Ipamorelin (lower is better) |
| Prolactin elevation | Minimal | Moderate | Ipamorelin |
| Receptor desensitization rate | Slower | Faster | Ipamorelin |
| CD36 cardiac activity | None | Present (animal data) | Context-dependent; not proven in humans |
| Sequence length | Pentapeptide (5 AA) | Hexapeptide (6 AA) | Tie (no clinical relevance) |
| Body composition human RCT data | None for wellness use | None for wellness use | Tie (both lacking) |
| US regulatory status (2026) | Removed from 503A/503B bulk list (2023) | Not FDA-approved; research compound | Neither has a clear legal US pathway |
| Combination with GHRH analogs | Common (CJC-1295 + ipamorelin) | Less commonly combined | Ipamorelin (more documented combination use) |
| Oral bioavailability | Negligible | Negligible | Tie (both require injection) |
| Overall safety profile for repeat dosing | More favorable (selective) | More side effects at equal doses | Ipamorelin |
Bottom line: ipamorelin wins on selectivity, tolerability, and practical repeat-dosing characteristics. Hexarelin wins on raw GH pulse amplitude. If the goal is clean GH stimulation with minimal hormonal noise, ipamorelin is the better-fit research compound. Hexarelin's potency advantage is mostly academic once desensitization and cortisol burden are factored in.
Dosing and Operational Label Literacy
Ipamorelin dosing context: Compounding and research protocols commonly use 200 to 300 mcg per injection subcutaneously, one to three times daily, with the most common timing being fasted (morning or pre-sleep). These numbers are not from a large human RCT; they derive from clinical and research compounding convention. The dose-response curve is not linear at high doses due to receptor saturation.
Hexarelin dosing context: Human pharmacology studies have used approximately 1 to 2 mcg/kg intravenously for single-dose assessments. Subcutaneous research protocols typically use 100 to 200 mcg per injection, lower than ipamorelin in absolute terms, partly because hexarelin's potency is higher and partly to limit cortisol and prolactin side effects.
Reconstitution math: A 5 mg vial of ipamorelin reconstituted with 2.5 mL of bacteriostatic water yields a 2 mg/mL (2000 mcg/mL) solution. A 250 mcg dose requires drawing 0.125 mL (12.5 units on a standard U-100 insulin syringe). Always verify: (desired dose in mcg) divided by (concentration in mcg/mL) equals volume in mL.
Reading a COA: A credible certificate of analysis for injection-grade peptides includes: HPLC purity of 98 percent or above, mass spectrometry confirming the correct molecular weight (ipamorelin approximately 711 Da; hexarelin approximately 887 Da), residual solvent analysis, and limulus amebocyte lysate (LAL) endotoxin testing below 1 EU/mg. A COA without MS confirmation is inadequate for any injectable use. A COA from the vendor's own in-house lab without third-party verification should be treated with skepticism. Ask for an ISO-accredited independent lab result.
What degraded peptide looks like: Visible particulates in a reconstituted solution, yellowing or browning of solution color, or a loss of the faint characteristic peptide odor are red flags. Lyophilized powder that has caked, clumped, or changed color from white/off-white before reconstitution suggests moisture infiltration or temperature excursion and should not be used.
Regulatory and Sourcing Reality
In the United States, neither ipamorelin nor hexarelin holds FDA approval for any indication. In 2023, the FDA finalized its removal of ipamorelin from the bulk drug substances lists under 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This means licensed compounding pharmacies may no longer legally compound ipamorelin-containing preparations for patient use under those exemptions. The practical consequence is that sources offering ipamorelin as a compounded medication in the US are either operating under a different regulatory framework or are non-compliant.
Hexarelin was never on the bulk compounding lists and remains a research compound with no approved US clinical pathway.
Outside the US, regulatory status varies significantly. Always verify current local regulations before sourcing or using either compound.
FAQ
Is hexarelin stronger than ipamorelin?
Yes. Hexarelin is a more potent GH secretagogue than ipamorelin at equivalent molar doses in animal and human studies. That potency comes with proportionally greater cortisol and prolactin release and faster desensitization of the GHS-R1a receptor, which limits its practical advantage.
Does ipamorelin raise cortisol?
Ipamorelin produces minimal cortisol and ACTH release compared to GHRP-6 and hexarelin. Bowers et al. characterized this selectivity in early GH secretagogue work. It remains a key reason ipamorelin is preferred in protocols where cortisol elevation is a concern.
Does hexarelin raise cortisol?
Yes, hexarelin activates CD36 and central CRH pathways in addition to GHS-R1a, producing measurable cortisol and ACTH increases in human studies. This is a clinically relevant difference from ipamorelin.
Can you combine ipamorelin with a GHRH analog?
Yes. Ipamorelin is commonly combined with CJC-1295 or modified GRF(1-29) because they act at different receptor sites and produce synergistic GH release. This combination is better studied than ipamorelin alone in terms of documented amplitude of GH pulses.
Does hexarelin desensitize faster than ipamorelin?
Evidence from animal studies and human pharmacology suggests hexarelin causes faster GHS-R1a desensitization with repeated dosing than ipamorelin, likely due to its higher intrinsic efficacy. Cycling protocols are generally recommended for both, but the concern is greater with hexarelin.
What is the typical dose range for ipamorelin?
Clinical research and compounding protocols typically use 200 to 300 mcg per injection, administered subcutaneously one to three times daily. These figures come from compounding-context use; no large human RCT has established an optimal dose for wellness indications.
What is the typical dose range for hexarelin?
Research studies have used doses ranging from approximately 1 to 2 mcg/kg per injection in humans. Practical compounding protocols often use 100 to 200 mcg per injection. Lower doses are preferred to limit cortisol and prolactin side effects.
Which peptide is better for body composition?
No head-to-head human RCT compares ipamorelin and hexarelin for body composition. Both increase GH acutely, but chronic body composition changes from either peptide in healthy adults are not established by robust human trial data. Claims outpace the evidence.
Are ipamorelin and hexarelin legal to purchase?
In the United States, neither ipamorelin nor hexarelin is FDA-approved for any indication. They are research chemicals or compounded medications depending on context. The FDA issued guidance in 2023 removing ipamorelin from the 503A/503B bulk compounding lists. Regulatory status varies by country.
How should ipamorelin or hexarelin be stored after reconstitution?
Both peptides should be refrigerated at 2 to 8 degrees Celsius after reconstitution with bacteriostatic water. Repeated freeze-thaw cycles and exposure to temperatures above 25 degrees Celsius accelerate peptide bond hydrolysis and aggregation. Use within two to four weeks of reconstitution is the generally recommended window.
Does hexarelin have cardiac effects?
Hexarelin binds CD36, a scavenger receptor expressed in cardiac tissue. Animal studies show cardioprotective effects in ischemia models. Human data are limited. This mechanism is not shared by ipamorelin, which is selective for GHS-R1a.
What does a legitimate COA for these peptides show?
A credible certificate of analysis includes HPLC purity (ideally above 98 percent), mass spectrometry confirmation of molecular weight, absence of residual solvents, and endotoxin testing. Any COA lacking MS confirmation of the correct molecular weight is insufficient for injection-grade material.
Sources
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. PubMed PMID: 9849822.
- Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1169-1174.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329.
- Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circulation Research. 1999;85(9):796-802.
- Muccioli G, Broglio F, Valetto MR, et al. Growth hormone-releasing peptides and the cardiovascular system. Annals of Endocrinology. 2000;61(1):27-31.
- Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321-1328.
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A and 503B: Ipamorelin. FDA.gov. 2023.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.